Why did Amgen terminate their phase 3 study of T-VEC?

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
Get help with your application

Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.

TSDentSurg

Full Member
10+ Year Member
Advertisement - Members don't see this ad
I read that Amgen terminated their phase 3 study of talimogene laherparepvec for SCC. They said it was due to the role HPV plays in the oncogenesis of H&N cancer.

Yes, a mandatory Gardasil vaccination would be wonderful to hopefully prevent new cases, but what do you do with all the current ones?

I absolutely hate it when companies stop trials for this...phase 3 trials should only be stopped for a) ineffectiveness or b) high rate of severe ADRs.

T-VEC had an awesome response rate and tolerable side-effects for use in SCC. http://meetinglibrary.asco.org/content/34768-65

Intratumoral injection of T-VEC to treat the gross neoplasms, and pre-targeted alpha RIT to treat any remaining micrometases.